Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoral plus ACE inhibitor vs Medrol plus ACE inhibitor in de novo nephrotic syndrome due to focal segmental glomerulosclerosis
2005-004460-22Phase 4Completed
- Sponsor
- Erasmus Hospital
- Start
- Dec 2005
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cyclosporine, methylprednisolone and lisinopril in focal segmental glomerulosclerosis (FSGS) and nephrosis (2 arms), sponsored by Erasmus Hospital. Primary endpoint: Complete remission at month 6. Started Dec 2005; status: completed.
02
Drugs
cyclosporinemethylprednisolonelisinopril
03
Conditions
focal segmental glomerulosclerosis (FSGS)nephrosis
Beyond the preview
Go deeper on 2005-004460-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004460-22.